Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Current Deferred Tax Assets (2020 - 2024)

Vistagen Therapeutics' Current Deferred Tax Assets history spans 4 years, with the latest figure at $74000.0 for Q1 2024.

  • For Q1 2024, Current Deferred Tax Assets changed N/A year-over-year to $74000.0; the TTM value through Mar 2024 reached $74000.0, changed N/A, while the annual FY2024 figure was $74000.0, N/A changed from the prior year.
  • Current Deferred Tax Assets for Q1 2024 was $74000.0 at Vistagen Therapeutics, down from $74500.0 in the prior quarter.
  • Across five years, Current Deferred Tax Assets topped out at $133500.0 in Q1 2021 and bottomed at $67100.0 in Q2 2023.
  • The 4-year median for Current Deferred Tax Assets is $116900.0 (2020), against an average of $105790.0.
  • The largest YoY upside for Current Deferred Tax Assets was 14.2% in 2021 against a maximum downside of 14.2% in 2021.
  • A 4-year view of Current Deferred Tax Assets shows it stood at $116900.0 in 2020, then rose by 14.2% to $133500.0 in 2021, then plummeted by 44.19% to $74500.0 in 2023, then dropped by 0.67% to $74000.0 in 2024.
  • Per Business Quant, the three most recent readings for VTGN's Current Deferred Tax Assets are $74000.0 (Q1 2024), $74500.0 (Q4 2023), and $74500.0 (Q3 2023).